Sequenom, Inc.  

(Public, NASDAQ:SQNM)   Watch this stock  
Find more results for SQNM
3.93
-0.02 (-0.51%)
After Hours: 3.80 -0.13 (-3.31%)
Apr 1, 6:48PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.82 - 3.96
52 week 2.36 - 4.19
Open 3.93
Vol / Avg. 1.55M/1.15M
Mkt cap 465.98M
P/E     -
Div/yield     -
EPS -0.12
Shares 117.97M
Beta 0.41
Inst. own 54%
Apr 29, 2015
Q1 2015 Sequenom Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 4, 2015
Q4 2014 Sequenom Inc Earnings Call
Mar 4, 2015
Q4 2014 Sequenom Inc Earnings Release
Jan 15, 2015
Sequenom Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 45.52% -9.48%
Operating margin 54.32% -9.04%
EBITD margin - -14.79%
Return on average assets 45.44% -9.40%
Return on average equity - -
Employees 448 -
CDP Score - -

Address

3595 John Hopkins Ct
SAN DIEGO, CA 92121-1121
United States - Map
+1-858-2029000 (Phone)
+1-858-2029001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company. The Company provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. Sequenom is engaged in researching, developing, and pursuing the commercialization of various noninvasive molecular diagnostic tests for prenatal genetic disorders, and diseases, women�s health-related disorders and diseases, ophthalmology, and other medical conditions such as oncology, infectious diseases, and autoimmunity. The Company conducts its business through two operating segments, Sequenom Laboratories and Sequenom Bioscience. The laboratories offer MaterniT21 PLUS test, the HerediT CF test, and the SensiGene RHD test. Sequenom bioscience manufactures and sells MassARRAY System, which provides quantitative DNA methylation analysis and comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control.

Officers and directors

Harry F. Hixson Jr., Ph.D. Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
William J. Welch Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Carolyn D. Beaver Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Dirk van den Boom Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 44
Bio & Compensation  - Reuters
Jeffrey D. Linton J.D. Senior Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Daniel Grosu Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Robin G. Weiner Senior Vice President, Corporate Governance and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
Richard A. Lerner M.D. Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Myla P. Lai-Goldman M.D. Director
Age: 56
Bio & Compensation  - Reuters
Ronald M. Lindsay Ph.D. Director
Age: 66
Bio & Compensation  - Reuters